CoChat

Central Pre-proglucagon Derived Peptides: Opportunities for Treatment of Obesity

Larsen, Philip, Vrang, Niels, Tang-Christensen, Mads · 2003 · Current Pharmaceutical Design

The DOI matches its Crossref record.

Abstract

Modern societies have moved from famine to feast and obesity and its co-morbidities now sweep the world as a global epidemic. Numerous scientific laboratories and pharmaceutical companies have taken the challenge and are now exploiting novel molecular targets for treatment of obesity. The pre-proglucagon system constitutes interesting candidates as potential targets for new anti-obesity drugs. In the periphery, pre-proglucagon derived peptides, Glucagon-Like Peptide-1 (GLP-1), Glucagon-Like Peptide-2 (GLP-2) and oxyntomodulin (OXM) are involved in a wide variety of physiological functions, including glucose homeostasis, gastric emptying, intestinal growth, insulin secretion as well as the regulation of food intake. Peripheral administration of GLP-1 derivatives and analogues to both rodents and man have shown promising effects on food intake and body weight suggesting that such therapies constitute potential anti-obesity treatment. In the central nervous system, pre-proglucagon and hence GLP-1, GLP-2 and OXM are exclusively found in a small population of nerve cells in the nucleus of the solitary tract. These constitute a neural pathway linking the "viscero-sensory" brainstem to hypothalamic nuclei involved in energy homeostasis. Intracerebroventricular administration of all of the three derived peptides robustly decrease food intake. It is evident that central GLP-1 agonism probably in combination with GLP-2 and/or OXM agonism constitute a potential pharmacological tool to reduce food intake and maybe also enhance energy expenditure. This and other aspects of the current state of the role of central pre-proglucagon in energy homeostasis are reviewed.

Overview

Integrity signals

Registry

Crossref · 10.2174/1381612033454775

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

See all 24

Metadata

Authors
Larsen, P., Vrang, N., & Tang-Christensen, M.
Venue
Current Pharmaceutical Design
Published
2003-07-01
Volume
9
Issue
17
Pages
1373-1382
ISSN
1381-6128 (ISSN-L)
OpenAlex
W2166985274
Cited by
24
References
0
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2016: 1 · 2013: 2 · 2012: 1
FWCI
0.95
Type
journal article
Language
en
Open access
closed
Locations
  • Current Pharmaceutical Design (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords
glucagon-like peptide-1, glucagon-like peptide-2, oxyntomodulin, obesity, anti-obesity drugs, nucleus tractus solitarius, central nervous system, dietary intake, energy homeostasis, hypothalamus, glucose homeostasis, insulin secretion, gastric emptying, energy expenditure
MeSH terms
Glucagon-Like Peptide-1 Receptor, Animals, Behavior, Animal, Central Nervous System, Eating, Glucagon-Like Peptides, Glucagon, Humans, Obesity, Peptide Fragments, Peptides, Protein Precursors, Receptors, Glucagon, Glucagon-Like Peptide 1, Proglucagon, Glucagon-Like Peptide 2, Oxyntomodulin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Central Pre-proglucagon Derived Peptides: Opportunities for Treatment of Obesity. https://app.cochat.ai/papers/10.2174/1381612033454775
The paper
Larsen, P., Vrang, N., & Tang-Christensen, M. (2003). Central Pre-proglucagon Derived Peptides: Opportunities for Treatment of Obesity. Current Pharmaceutical Design. https://doi.org/10.2174/1381612033454775

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.